Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625
This examiner grants 58% of resolved cases
David K. O Dell works in Art Unit 1621 within Tech Center 1600. He has a high volume of 1346 resolved cases with an allowance rate of 57.7 percent. The median days to allowance is 1004, which suggests a consistent timeline for reaching an allowance. Practitioners should expect a prosecution period that spans many days in Tech Center 1600.
The interview lift is 36.0 percent, showing that interviews are a strong strategy to improve upon the 57.7 percent baseline. For the 1346 cases resolved, the 1004-day median pendency is a reliable metric for planning. Practitioners should prioritize interviews to leverage the 36.0 percent lift and improve their chances in Art Unit 1621. The 57.7 percent allowance rate indicates a fair probability of success for applicants seeking patents under this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18520315 | ORGANIC METAL COMPLEX AND ORGANIC LIGHT EMITTING ELEMENT | Non-Final OA | CANON KABUSHIKI KAISHA |
| 18232230 | CHIRAL PHOSPHORIC ACIDS IMMOBILIZED ON SOLID SUPPORT FOR THE SELECTIVE PROTECTION OF HYDROXYL GROUPS | Final Rejection | REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18161380 | Heteroatom-Containing Silane Compound | Final Rejection | Henkel AG & Co. KGaA |
| 18565484 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | Non-Final OA | Eli Lilly and Company |
| 18264413 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | Non-Final OA | The Board of Regents of The University of Texas System |
| 17923188 | IAP ANTAGONIST COMPOUNDS AND INTERMEDIATES AND METHODS FOR SYNTHESIZING THE SAME | Final Rejection | Otsuka Pharmaceutical Co., Ltd. |
| 18288977 | METHOD FOR PREPARING TERTIARY AMINE WITH SECONDARY AMINE AS RAW MATERIAL | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18555058 | COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A MEK INHIBITOR | Non-Final OA | PFIZER, INC. |
| 18287897 | Therapeutics for Hyponatremia and Polycystic Kidney Disease | Non-Final OA | University of Cincinnati |
| 18691769 | BET INHIBITORS FOR TREATING PAB1 DEFICIENT CANCER | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18262913 | METHOD FOR THE PRODUCTION OF D-ERYTHRO-SPHINGOSINE AND ANALOGS THEREOF | Final Rejection | CarboCode S.A. |
| 18276532 | QUINAZOLIN-4-ONE AND THIENO[2,3-D]PYRIMIDIN-4-ONE INHIBITORS OF ERBB4 (HER4) FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | UNIVERSITEIT ANTWERPEN |
| 18696213 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | Final Rejection | BAYER PHARMA AKTIENGESELLSCHAFT |
| 17612155 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | Non-Final OA | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy